SCALE Performance

NAD+ Pen certificate of analysis, lot PL-2610-135

Certificate PL-26-00249 reports the release tests for NAD+ Pen lot PL-2610-135: 99.76% purity by reverse-phase HPLC and identity confirmed by LC-MS, tested October 7, 2026. The lot number printed on each unit matches this certificate.

Certificate numberPL-26-00249
Lot numberPL-2610-135
CompoundNAD+ Pen 300 mg
Purity (RP-HPLC)99.76%
Identity (LC-MS)Conforms (663.42 Da) · expected 663.43 Da, found 663.42 Da
MethodRP-HPLC (UV 214 nm) + LC-MS
TestedOctober 7, 2026
Retest byOctober 5, 2028
Tested byManufacturer’s in-house laboratory (not an independent third-party test)
ConclusionConforms

Tests run on this lot

TestMethodSpecificationResult
Identity (mass)LC-MS, ESI positiveTheoretical ± 1.0 Da663.42 Da (PASS)
PurityRP-HPLC, UV 254–306 nm, area%≥ 99.0%99.76% (PASS)
Largest impurityRP-HPLC, area%≤ 1.0%0.11% (RT 5.70) (PASS)
Assay (label claim)Assay vs label claim95–105 mg/mL100.66 mg/mL (PASS)
Bacterial endotoxinLAL, kinetic≤ 5.0 EU/mg0.046 EU/mg (PASS)
SterilityUSP <71>, 14-dayNo growthNo growth (PASS)

What these results mean

HPLC purity is the share of UV-detectable material that elutes as the target compound; it is not the same as net peptide content, which also accounts for water and counter-ions. Identity means the measured mass matched the mass calculated for the compound. A certificate reports only the tests run on this lot; endotoxin, sterility and contaminant panels are not part of standard lot release. How to read a certificate of analysis.

NAD+ Pen · Verify this certificate · All certificates

All NAD+ Pen certificates

Other NAD+ Pen lots

  • PL-26-00250, lot PL-2610-136, 99.68%, tested October 6, 2026

All products currently listed on this site are for research purposes only. Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.